433 related articles for article (PubMed ID: 21898529)
1. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
2. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
3. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
[TBL] [Abstract][Full Text] [Related]
4. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
5. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
Dubovsky JA; McNeel DG
Prostate; 2007 Dec; 67(16):1781-90. PubMed ID: 17929270
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
Gutierrez-Cosío S; de la Rica L; Ballestar E; Santamaría C; Sánchez-Abarca LI; Caballero-Velazquez T; Blanco B; Calderón C; Herrero-Sánchez C; Carrancio S; Ciudad L; Cañizo C; San Miguel JF; Pérez-Simón JA
Leuk Res; 2012 Jul; 36(7):895-9. PubMed ID: 22503131
[TBL] [Abstract][Full Text] [Related]
7. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T; Schafhausen P; Uhlich F; Stasche T; Akbulak R; Bartels BM; Hildebrandt Y; Gontarewicz A; Kobold S; Meyer S; Gordic M; Bartels K; Lajmi N; Cao Y; Kröger N; Bokemeyer C; Brümmendorf TH; Atanackovic D
Leuk Res; 2010 Dec; 34(12):1647-55. PubMed ID: 20409582
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
dos Santos NR; Torensma R; de Vries TJ; Schreurs MW; de Bruijn DR; Kater-Baats E; Ruiter DJ; Adema GJ; van Muijen GN; van Kessel AG
Cancer Res; 2000 Mar; 60(6):1654-62. PubMed ID: 10749136
[TBL] [Abstract][Full Text] [Related]
9. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
10. 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Coral S; Sigalotti L; Altomonte M; Engelsberg A; Colizzi F; Cattarossi I; Maraskovsky E; Jager E; Seliger B; Maio M
Clin Cancer Res; 2002 Aug; 8(8):2690-5. PubMed ID: 12171902
[TBL] [Abstract][Full Text] [Related]
11. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
12. Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma.
Utsunomiya T; Inoue H; Tanaka F; Yamaguchi H; Ohta M; Okamoto M; Mimori K; Mori M
Ann Surg Oncol; 2004 Oct; 11(10):934-40. PubMed ID: 15466353
[TBL] [Abstract][Full Text] [Related]
13. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
[TBL] [Abstract][Full Text] [Related]
15. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
16. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.
Fratta E; Sigalotti L; Colizzi F; Covre A; Nicolay HJ; Danielli R; Fonsatti E; Altomonte M; Calabrò L; Coral S; Maio M
J Cell Physiol; 2010 May; 223(2):352-8. PubMed ID: 20127705
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
18. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
19. Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma.
Wu LQ; Lu Y; Wang XF; Lv ZH; Zhang B; Yang JY
Life Sci; 2006 Jul; 79(8):744-8. PubMed ID: 16546222
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
Coral S; Parisi G; Nicolay HJ; Colizzi F; Danielli R; Fratta E; Covre A; Taverna P; Sigalotti L; Maio M
Cancer Immunol Immunother; 2013 Mar; 62(3):605-14. PubMed ID: 23138873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
